Rubaiya Anika | Health | Innovative Research Award

Innovative Research Award

Rubaiya Anika
Mount Sinai Hospital, United States

Rubaiya Anika
Affiliation Mount Sinai Hospital
Country United States
Documents 1
Subject Area Health
Event International Research Hypothesis Excellence Award
ORCID 0009-0005-9072-732X

Rubaiya Anika is a researcher affiliated with Mount Sinai Hospital in the United States whose documented research contribution addresses environmental exposure and biological aging. Her listed journal article examines urinary organophosphate metabolites in relation to laboratory-derived phenotypic aging acceleration among U.S. adults using data from the National Health and Nutrition Examination Survey (NHANES) covering 1999–2018. The work was published in the International Journal of Environmental Research and Public Health in August 2026 and provides a research contribution at the intersection of environmental health, exposure science, epidemiology, and aging research. [1]

Abstract

The research contribution associated with Rubaiya Anika investigates the relationship between urinary organophosphate metabolites and laboratory-derived phenotypic aging acceleration in U.S. adults. The study, titled Urinary Organophosphate Metabolites and Laboratory-Derived Phenotypic Aging Acceleration in U.S. Adults: Evidence from NHANES 1999–2018, uses population-based NHANES data to examine an environmental exposure question within an aging-related epidemiological framework. The article was published in the International Journal of Environmental Research and Public Health in August 2026 and is identified by DOI 10.3390/ijerph23091126. [1]

Keywords

  • Innovative Research Award
  • Rubaiya Anika
  • Organophosphate metabolites
  • Phenotypic aging
  • Environmental health

Introduction

Environmental exposures are an important area of public-health research because chemical exposures may vary across populations and may be investigated in relation to measurable biological and health outcomes. Organophosphate metabolites measured in urine can serve as biomarkers of exposure to organophosphate compounds, while phenotypic measures of aging can provide quantitative indicators for studying biological aging in epidemiological populations. The reported study brings these concepts together by analyzing nationally collected U.S. health data across multiple NHANES cycles from 1999 through 2018. [1]

Research Profile

Rubaiya Anika is identified in the supplied publication record as an author affiliated with Mount Sinai Hospital, United States. The documented subject area is Health, with the research contribution positioned within environmental and population health. The available publication record contains one indexed document supplied for this recognition profile.[1]

Research Contributions

The principal documented contribution is the study of urinary organophosphate metabolites in relation to laboratory-derived phenotypic aging acceleration. This research connects environmental exposure assessment with an aging-related outcome and uses nationally collected health-survey data as its analytical foundation. [1]

  • Evaluation of urinary organophosphate metabolite measurements as indicators of environmental exposure.
  • Investigation of phenotypic aging acceleration as a measurable aging-related outcome.
  • Use of NHANES data spanning 1999–2018 to support population-based analysis.
  • Integration of environmental epidemiology and biological aging research.[1]

Publications

The available record identifies one journal article associated with Rubaiya Anika:

Urinary Organophosphate Metabolites and Laboratory-Derived Phenotypic Aging Acceleration in U.S. Adults: Evidence from NHANES 1999–2018

The publication lists Rubaiya Anika, Matthew Untalan, Emanuela Taioli, and Stephanie Tuminello as contributors. The DOI provides a persistent identifier for the journal article and supports direct access to its bibliographic record. [1]

Research Impact

The documented research has potential relevance to environmental and population health because it investigates whether measurable environmental exposure biomarkers are associated with an aging-related phenotype in adults. Research of this type can contribute to hypothesis generation, exposure surveillance, and the identification of questions that may warrant further investigation through longitudinal, mechanistic, or experimental studies. [1]

Award Suitability

The documented publication provides a substantive basis for considering Rubaiya Anika for recognition under an Innovative Research Award framework. The work applies an interdisciplinary research approach by connecting environmental exposure biomarkers with a quantitative indicator of phenotypic aging in a U.S. adult population. [1]

  • Research innovation: The study links environmental exposure assessment with laboratory-derived phenotypic aging measures.
  • Interdisciplinary relevance: The research spans environmental health, epidemiology, exposure science, and aging research.
  • Population relevance: NHANES provides a nationally collected U.S. population dataset for epidemiological investigation.
  • Research communication: The work is documented through a peer-reviewed journal publication with a persistent DOI.
  • Future research value: The findings can help motivate additional research into environmental determinants of biological aging.

Conclusion

Rubaiya Anika’s documented research contribution focuses on the relationship between urinary organophosphate metabolites and laboratory-derived phenotypic aging acceleration among U.S. adults using NHANES data from 1999–2018. The resulting publication demonstrates an interdisciplinary approach to environmental and population health research and provides a basis for further investigation of environmental influences on aging-related outcomes. [1]

References

  1. Anika, R., Untalan, M., Taioli, E., & Tuminello, S. (2026). Urinary Organophosphate Metabolites and Laboratory-Derived Phenotypic Aging Acceleration in U.S. Adults: Evidence from NHANES 1999–2018. International Journal of Environmental Research and Public Health, 23(9), 1126.
    https://doi.org/10.3390/ijerph23091126

Lina Vieira | Medicine and Health Sciences | Research Hypothesis Excellence Award

Lina Vieira | Medicine and Health Sciences | Research Hypothesis Excellence Award

Prof Lina Vieira, ESTeSL/IPL, Portugal

Prof. Lina Vieira is a distinguished biomedical researcher and educator with a PhD in Biomedical Engineering and Biophysics from the University of Lisbon 🎓, awarded with Distinction and Honors 🏅. Her work primarily advances nuclear medicine, with a special focus on myocardial perfusion scintigraphy and SPECT imaging 🧠❤️. She holds a professorial position at the Lisbon School of Health Technology, actively contributing to both teaching and scientific innovation 📚🔬. Prof. Vieira has led several EU-funded projects, including PIANOFORTE, focusing on safe, optimized radiology for vulnerable populations 🤰📡. Her research blends technology, biophysics, and human-centered approaches like anxiety reduction and music therapy in imaging 🧘‍♀️🎵. An award-winning author and supervisor, she has trained numerous graduate students and remains a leading voice in radiological safety and optimization ⚛️. Her scientific rigor, innovation, and societal impact make her an ideal candidate for the Research Hypothesis Excellence Award 🏆🔍.

Publication Profile

Orcid

Education

Prof. Lina Vieira earned her PhD in Biomedical Engineering and Biophysics from the University of Lisbon in 2011 with Distinction and Honors 🎓🌟. Her thesis focused on optimizing myocardial perfusion studies using ECG-gated nuclear medicine imaging ❤️🧠. She also holds a Postgraduate Degree in Medical Physics and Biomedical Engineering (2005) and a Bachelor’s in Nuclear Medicine (2000) from the Lisbon School of Health Technology ⚛️📘. As part of her academic growth, she qualified through rigorous public examinations to become a Coordinating Professor in Nuclear Medicine within the Radiation Sciences and Biosignal Technologies Department at ESTeSL 👩‍🏫🧪. Her scholarly training is grounded in biophysics, imaging technology, and healthcare applications, forming a strong foundation for her future academic, research, and leadership achievements 🔬💡.

Experience

Prof. Vieira serves as a Coordinating Professor at the Lisbon School of Health Technology, leading Nuclear Medicine teaching and research initiatives 👩‍🏫🧠. She has been an integrated member of the Health & Technology Research Center since 2019, previously with the Institute of Biophysics and Biomedical Engineering at the University of Lisbon 🧬📊. Her work spans across modeling, signal processing, and human-centered diagnostic imaging, including participation in CIMOSM and GI-MOSM research centers 🧠⚙️. Notably, she coordinates the EU-funded PIANOFORTE project on safe radiology for pregnant patients 🤰📡, and leads innovative research on anxiety and music’s impact on image quality 🎵😌. Prof. Vieira is a mentor to many MSc students and has supervised several dissertations on SPECT imaging, Parkinson’s diagnostics, and PET education 📚📝. Her cross-disciplinary expertise makes her a leader in merging clinical practice with scientific excellence 🏥🔍.

Awards and Honors

Prof. Vieira has received multiple prestigious awards honoring her innovative research in nuclear medicine and imaging technology 🏅📡. She earned the Best Scientific Article Award from Saúde & Tecnologia in 2018, 2017, and 2015 for studies on technologist exposure, myocardial perfusion, and PET/CT in melanoma surveillance 🎖️📘. Her paper, “Value of a Lower Limb Immobilization Device for Optimization of SPECT/CT Image Fusion,” was named one of the Top 3 Papers by JNMT in 2015 and recognized at the 2016 Annual SNMMI Congress in San Diego 🇺🇸✨. These accolades reflect her commitment to high-impact, hypothesis-driven research that enhances clinical outcomes and patient safety 🧠❤️. With consistent recognition over the years, Prof. Vieira continues to lead innovations in nuclear medicine, both theoretically and practically 🔬📈.

Research Focus

Prof. Vieira’s research centers on optimizing nuclear medicine imaging, particularly myocardial perfusion scintigraphy (MPS), SPECT acquisition techniques, and patient-centered innovations in diagnostic imaging ❤️📸. She investigates the impact of psychophysiological variables, such as anxiety, on image quality and explores non-pharmacological interventions like music therapy to improve patient outcomes 🎶🧘‍♂️. A strong advocate for radiological safety, she spearheads projects like PIANOFORTE, which targets personalized radiology for pregnant patients 🤰⚛️. She also delves into educational methodologies, evaluating the effect of videos and social media in communicating ionizing radiation risks effectively 📲🧠. Her interdisciplinary focus combines engineering, patient psychology, radiological science, and public communication—making her work vital for improving both technical precision and patient experience in medical imaging 💡🩺. Her hypothesis-driven approach is rooted in measurable impacts, clinical relevance, and ethical responsibility 🔍📐.

Publication Top Notes

  • 📄 Myocardial Perfusion Scintigraphy: Impact of Anxiety on Image Quality (JPM, 2025 – submitted)

  • 📄 Potential Benefits of Social Media in Educating Healthcare Professionals and Students on Medical Imaging with Ionizing Radiation (Radiography Journal, 2025)

  • 📄 Effects of a Music-Based Intervention on Psychophysiological Outcomes of Patients Undergoing Imaging Procedures: A Systematic Review (Radiography Journal, 2024)

  • 📄 Effectiveness of Educational Videos on Patient’s Preparation for Diagnostic Procedures: Systematic Review and Meta-Analysis (Preventive Medicine Reports, 2022)

Yu Pan | Medicine and Health Sciences | Young Scientist Award

Yu Pan | Medicine and Health Sciences | Young Scientist Award

Dr Yu Pan, Fujian Medical University Union Hospital, China

Dr. Yu Pan is a pioneering medical scientist and attending physician at the Department of General Surgery, Fujian Medical University Union Hospital, China. His groundbreaking research bridges immunotherapy and pancreatic cancer treatment, focusing on mechanisms shaping the tumor microenvironment and translating them into clinical applications. As the principal investigator of multiple prestigious grants, Dr. Pan leads a laboratory exploring mRNA vaccine development and immune regulation in pancreatic malignancies. With over a dozen high-impact publications, including in Nature Nanotechnology and JITC, his work is rapidly transforming the therapeutic landscape. An active mentor and educator, he has guided eight Master’s students, several of whom now pursue PhDs or hold clinical positions at top hospitals. Recognized for academic excellence and innovation, Dr. Pan exemplifies the qualities of a future leader in oncology and immunology. His contributions reflect a deep commitment to both science and society.

Publication Profile

Orcid

Education

Dr. Yu Pan is a dedicated medical professional with a strong academic background in Medical Sciences 🧠🔬. He began he journey in medicine at Anhui Medical University, China, where he earned he Bachelor’s degree between 2008 and 2013 🎓🇨🇳. He passion for advancing healthcare led he to pursue further studies at Fujian Medical University. From 2014 to 2017, he completed he Master’s degree in Medical Sciences, specializing in General Surgery 🏥🩺. Demonstrating exceptional commitment to surgical research and clinical excellence, Dr. Pan continued at the same university to obtain her Ph.D. in Medical Sciences from 2017 to 2020 🎓🔍. During her academic career, she gained extensive experience in surgical techniques, research methodologies, and patient care, contributing significantly to the field of general surgery 📚. He educational path reflects a continuous pursuit of knowledge and skill development, underscoring he role as a dedicated surgeon and researcher committed to medical innovation and patient well-being ❤️‍🩹.

Experience

Dr. Yu Pan is a dedicated surgical professional with extensive experience in clinical practice, teaching, and mentorship. From 2020 to 2022, Dr. Pan completed a surgical residency at the Department of Surgery, Fujian Medical University Union Hospital 🏥. Since 2022, he has served as a Staff Attending Physician in the Department of General Surgery 👨‍⚕️. Alongside his clinical duties, Dr. Pan has been actively involved in teaching as an Instructor for Clinical Skills Training Classes (2022–2024) at Fujian Medical University 🎓. He has also served as a thesis advisor for Master’s students since 2021, mentoring eight students in total. Five have graduated, with three pursuing PhDs and two now practicing at top institutions, including Jinhua Hospital and Fudan University Shanghai Cancer Center 🎯. His mentees have published in prestigious journals such as JITC, Functional Integrated Genomics, Frontiers in Pharmacology, and Cell Death & Disease 📚🔬, reflecting Dr. Pan’s strong academic impact.

Awards and Honors

Dr. Yu Pan is a highly accomplished medical researcher recognized for his consistent contributions to science and healthcare advancement 🧬🩺. He currently leads the 2025 Overseas Study Program for Young and Middle-Aged Medical Talents in Fujian Province 🌏✨. In 2023, he was selected for the Excellent Young Scholars Cultivation Project by Fujian Medical University Union Hospital (No. 2022XH025) 🧑‍🔬🏅. His expertise earned national recognition through the prestigious 2021 National Natural Science Foundation of China grant (No. 82103310) 🇨🇳🔍. That same year, he secured funding from the Natural Science Foundation of Fujian Province (No. 2021J01774) and played a pivotal role in the Joint Funds of the Scientific and Technological Innovation Program of Fujian Province (No. 2020Y9081) 💡🔬. Additionally, Dr. Pan led the 2020 Fujian Provincial Health Technology Project (No. 2020GGA029), further highlighting his dedication to medical research and innovation in the region.

Research Focus

Dr. Yu Pan’s research centers on pancreatic cancer and inflammatory-immune responses, with a strong emphasis on immune regulation, tumor microenvironment, and therapeutic targets 🧬🩸. His studies explore the role of Annexin A1, CD47-targeted therapies, and immune checkpoints in pancreatic disorders, especially pancreatic ductal adenocarcinoma (PDAC) and neuroendocrine neoplasms 🧫🧠. Through single-cell analysis, preclinical models, and clinical translation, Dr. Pan investigates how immune dynamics shape disease progression and treatment outcomes 🧪📊. His work contributes significantly to immunotherapy and precision medicine in gastrointestinal oncology, aiming to improve prognosis and treatment for patients with severe pancreatic conditions 💊🧠🧑‍⚕️.

Publication Top Notes